1. Home
  2. TNXP vs MLP Comparison

TNXP vs MLP Comparison

Compare TNXP & MLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • MLP
  • Stock Information
  • Founded
  • TNXP 2007
  • MLP 1909
  • Country
  • TNXP United States
  • MLP United States
  • Employees
  • TNXP N/A
  • MLP N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • MLP Real Estate
  • Sector
  • TNXP Health Care
  • MLP Finance
  • Exchange
  • TNXP Nasdaq
  • MLP Nasdaq
  • Market Cap
  • TNXP 335.6M
  • MLP 343.9M
  • IPO Year
  • TNXP N/A
  • MLP 1972
  • Fundamental
  • Price
  • TNXP $26.54
  • MLP $17.10
  • Analyst Decision
  • TNXP Buy
  • MLP
  • Analyst Count
  • TNXP 1
  • MLP 0
  • Target Price
  • TNXP $70.00
  • MLP N/A
  • AVG Volume (30 Days)
  • TNXP 1.9M
  • MLP 16.5K
  • Earning Date
  • TNXP 08-11-2025
  • MLP 08-14-2025
  • Dividend Yield
  • TNXP N/A
  • MLP N/A
  • EPS Growth
  • TNXP N/A
  • MLP N/A
  • EPS
  • TNXP N/A
  • MLP N/A
  • Revenue
  • TNXP $9,831,000.00
  • MLP $16,843,000.00
  • Revenue This Year
  • TNXP $21.19
  • MLP N/A
  • Revenue Next Year
  • TNXP $722.94
  • MLP N/A
  • P/E Ratio
  • TNXP N/A
  • MLP N/A
  • Revenue Growth
  • TNXP N/A
  • MLP 74.59
  • 52 Week Low
  • TNXP $6.76
  • MLP $14.05
  • 52 Week High
  • TNXP $130.00
  • MLP $25.78
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 32.47
  • MLP 51.09
  • Support Level
  • TNXP $34.50
  • MLP $16.79
  • Resistance Level
  • TNXP $29.70
  • MLP $17.50
  • Average True Range (ATR)
  • TNXP 3.35
  • MLP 0.56
  • MACD
  • TNXP -1.55
  • MLP 0.06
  • Stochastic Oscillator
  • TNXP 4.29
  • MLP 76.32

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About MLP Maui Land & Pineapple Company Inc.

Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales which includes land planning and entitlement, development, and sales activities; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.

Share on Social Networks: